Target intelligence / Profile preview

Beta-defensin 125 (DEFB125)

Target
DEFB125
Molecular classification
Antimicrobial peptide, Defensin family, Other (Cysteine-rich cationic polypeptide)
01

Overview

Beta-defensin 125 is a human antimicrobial peptide, encoded by the DEFB125 gene on chromosome 20, with a length of typically 57–157 amino acids (depending on organism and splice variant)[3][5][6][1]. It is a member of the beta-defensin family of cysteine-rich cationic proteins, crucial to the innate immune system. These peptides disrupt microbial cell membranes, providing broad-spectrum defense against bacteria, fungi, and some viruses[4][7]. Beta-defensins, including DEFB125, are produced at mucosal surfaces and by epithelial cells in response to infection and inflammation, although the tissue and inducibility profile for DEFB125 itself is not robustly established. No specific clinical uses or drug interactions for DEFB125 have been reported; its primary function remains natural host defense[6][7][4].

Other names
DEFB125DEFB25Beta-defensin 125Beta-defensin 25Defensin, beta 125beta-defensin 125beta-defensin 25DEFB-25
02

Mechanism of action

Not known as a direct drug target; general mechanism for defensins is disruption of microbial membranes, leading to lysis

03

Biological functions

Antimicrobial activity (kills or inhibits bacteria)Immune response (constitutive component of host defense)
04

Disease associations

Infection (host defense against pathogenic organisms)Other (potential role in inflammation and immune-related disorders, consistent with defensins generally)
05

Safety considerations

No specific safety concerns documented for DEFB125 as a therapeutic target; general challenges for antimicrobial peptides include potential for off-target cytotoxicity or immunogenicity

Beyond the preview

Go deeper on Beta-defensin 125 (DEFB125).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-defensin 125 (DEFB125).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call